Botanix (ASX: BOT) hosted a webinar to update shareholders on the Company’s preparations for the FDA mid-cycle review of Sofpironium Bromide in Q1 2023.
The webinar was hosted by Gautam Aggarwal, a Partner with Triangle Insights Group, who has conducted insightful market research in relation to the Sofpironium Bromide.
Other presenters included Botanix Executive Director, Matt Callahan and Botanix Chief Operating Officer, Dr Howie McKibbon.
Botanix Executive Director, Matt Callahan, recently participated in the ShareCafe Small Cap ‘Hidden Gems’ Webinar.
His presentation provided an overview of our clinical pipeline, including the significant potential for new dermatology products and opportunities for adding new assets to our pipeline. Matt also shared an update on upcoming clinical and operational milestones for 2022.
Botanix has today released an updated corporate presentation to the ASX, to support a non-deal investor roadshow underway this week.
The latest developments in our antimicrobial resistance (AMR) and dermatology R&D programs, include:
Botanix Pharmaceuticals has released a corporate presentation to the ASX this morning, which is being shared with investors as part of meetings over the course of the next week.
Key highlights include:
Our Company remains in a strong financial position, holding a cash balance of A$21.56m at 30 June 2021, and is progressing strategically forward to deliver these core programs.
Botanix Pharmaceuticals (ASX:BOT) has today shared a market update and new data pertaining to the BTX 1801 antimicrobial program, which is currently being studied as part of a Phase 2a clinical trial in Perth.
The new data demonstrates BTX 1801 eliminates methicillin-resistant Staphylococcus aureus (‘MRSA’ or ‘Golden Staph’) from human skin explants infected with MRSA. It also confirms synthetic CBD’s novel mechanism of action, where treatment with CBD rapidly disrupts the bacteria’s membrane resulting in cell death.
The latest news was captured as part of a presentation shared by Botanix President and Executive Chairman, Vince Ippolito, for the ASX Small and Mid-Cap Conference today – which features a close-up look at the mechanism of action.
View the ASX Small & Mid-Cap Conference presentation:
The Botanix team is extremely encouraged by this new data and remains confident that BTX 1801 will be a valuable treatment option for the prevention of post-surgical infections, which are often serious and can be life-threatening. Addressing antimicrobial resistance (AMR) remains a foremost priority for the Company, alongside the largest health agencies in the world.
AUSTRALIA
D2, 661 Newcastle Street, Leederville WA 6007
USA
3602 Horizon Drive, Suite 160, King of Prussia, PA 19406
Be notified of important news from Botanix.
AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com